维普中文期刊产品整合服务
74篇 您的检索式:作者名="Paul Sugarbaker"
    题名 作者 年代 出处 被引量
1Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum显示文摘Colorectal cancer(CRC) is the third most common cancer and the fourth most common cause of cancerrelated death worldwide. Besides the lymphatic and haematogenous routes of dissemination,CRC frequently gives rise to transcoelomic spread of tumor cells in the peritoneal cavity,which ultimately leads to peritoneal carcinomatosis(PC). PC is associated with a poor prognosis and bad quality of life for these patients in their terminal stages of disease. A loco-regional treatment modality for PC combining cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy has resulted in promising clinical results. However,this novel approach is associated with significant morbidity and mortality. A comprehensive understanding of the molecular events involved in peritoneal disease spread is paramount in avoiding unnecessary toxicity. The emergence of PC is the result of a molecular crosstalk between cancer cells and host elements,involving several well-defined steps,together known as the peritoneal metastatic cascade. Individual or clumps of tumor cells detach from the primary tumor,gain access to the peritoneal cavity and become susceptible to the regular peritoneal transport. They attach to the distant peritoneum,subsequently invade the subperitoneal space,where angiogenesis sustains proliferation and enables further metastatic growth. These molecular events are not isolated events but rather a continuous and interdependent process. In this manuscript,we review current data regarding the molecular mechanisms underlying the development of colorectal PC,with a special focus on the peritoneum and the role of the surgeon in peritoneal disease spread.Lieselotte Lemoine Paul Sugarbaker Kurt Van der Speeten 2016World Journal of Gastroenterology2016,22,34:12
2Update on the prevention of local recurrence and peritoneal metastases in patients with colorectal cancer显示文摘The prevention of a disease process has always been superior to the treatment of the same disease throughout the history of medicine and surgery.Local recurrence and peritoneal metastases occur in approximately8%of colon cancer patients and 25%of rectal cancer patients and should be prevented.Strategies to prevent colon or rectal cancer local recurrence and peritoneal metastases include cytoreductive surgery and hyperthermic perioperative chemotherapy(HIPEC).These strategies can be used at the time of primary colon or rectal cancer resection if the HIPEC is available.At institutions where HIPEC is not available with the treatment of primary malignancy,a proactive second-look surgery is recommended.Several phaseⅡstudies strongly support the proactive approach.If peritoneal metastases were treated along with the primary colon resection,5-year survival was seen and these results were superior to the results of treatment after peritoneal metastases had developed as recurrence.Also,prophylactic HIPEC improved survival with T3/T4 mucinous or signet ring colon cancers.A second-look has been shown to be effective in two published manuscripts.Unpublished data from MedStar Washington Cancer Institute also produced favorable date.Rectal cancer with peritoneal metastases may not be so effectively treated.There are both credits and debits of this proactive approach.Selection factors should be reviewed by the multidisciplinary team for individualized management of patients with or at high risk for peritoneal metastases.Paul H Sugarbaker 2014World Journal of Gastroenterology2014,20,28:7
3Morbidity and Mortality Analysis of 200 Treatments With Cytoreductive Surgery and Hyperthermic Intraoperative Intraperitoneal Chemotherapy Using the Coliseum Technique显示文摘Arvil D. Stephens MD Robert Alderman PA-C David Chang MD Gary D. Edwards PA-C Jesus Esquivel MD Gilbert Sebbag MD Mark A. Steves MD Paul H. Sugarbaker MD 1999Annals of Surgical Oncology1999,,8:5
4Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model显示文摘Pierre Jacquet Andrew Averbach O. Anthony Stuart David Chang Paul H. Sugarbaker 1997Cancer Chemotherapy and Pharmacology1997,,2:4
5Thermal Enhancement of New Chemotherapeutic Agents at Moderate Hyperthermia显示文摘Faheez Mohamed MBChB MRCS Pierre Marchettini MD O. Anthony Stuart BS M. Urano MD Paul H. Sugarbaker MD FACS FRCS 2003Annals of Surgical Oncology2003,,4:3
6A Systematic Review on the Efficacy of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei显示文摘Tristan D. Yan BSc (Med) MBBS Deborah Black BSc DipEd MStat PhD Renaldo Savady MD Paul H. Sugarbaker MD 2007Annals of Surgical Oncology2007,,2:2
7Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics显示文摘Vinicius Lima Vazquez O. Anthony Stuart Faheez Mohamed Paul H. Sugarbaker 2003Cancer Chemotherapy and Pharmacology2003,,2:2
8Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C显示文摘O. Anthony Stuart BS Arvil D. Stephens BS Laura Welch MD Paul H. Sugarbaker MD 2002Annals of Surgical Oncology2002,,2:2
9Treatment of primary colon cancer with peritoneal carcinomatosis显示文摘Sophie R. Pestieau M.D. Dr. Paul H. Sugarbaker M.D 2000Diseases of the Colon & Rectum2000,,10:2
10Indications for Early Postoperative Intraperitoneal Chemotherapy of Advanced Gastric Cancer: Results of a Prospective Randomized Trial显示文摘Wansik Yu Ilwoo Whang Ho Young Chung Andrew Averbach Paul H. Sugarbaker 2001World Journal of Surgery2001,,8:2
11Successful management of microscopic residual disease in large bowel cancer显示文摘Paul H. Sugarbaker 1999Cancer Chemotherapy and Pharmacology1999,,1:2
12Prognostic Indicators for Patients Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma?显示文摘Tristan D. Yan BSc (Med) MBBS Erwin A. Brun MD Carlos A. Cerruto MD Namik Haveric MD David Chang MS Paul H. Sugarbaker MD 2007Annals of Surgical Oncology2007,,1:2
13Intraperitoneal cancer dissemination: Mechanisms of the patterns of spread显示文摘C. Pablo Carmignani Tessa A. Sugarbaker Christina M. Bromley Paul H. Sugarbaker 2003Cancer and Metastasis Reviews2003,,:2
14Results of Treatment of 385 Patients With Peritoneal Surface Spread of Appendiceal Malignancy显示文摘Paul H. Sugarbaker MD David Chang 1999Annals of Surgical Oncology1999,,8:2
15A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer显示文摘Tristan D. Yan Deborah Black Paul H. Sugarbaker Jacqui Zhu Yutaka Yonemura George Petrou David L. Morris 2007Annals of Surgical Oncology2007,,10:2
16A Clinicopathologic Analysis of 109 Cases with Emphasis on Distinguishing Pathologic Features, Site of Origin, Prognosis, and Relationship to “Pseudomyxoma Peritonei”显示文摘Brigite M. Ronnett Christopher M. Zahn Robert J. Kurman Mary E. Kass Paul H. Sugarbaker Barry M. Shmookler 1995The American Journal of Surgical Pathology1995,,12:2
17Prevention of Peritoneal Metastases from Colon Cancer in High-Risk Patients: Preliminary Results of Surgery plus Prophylactic HIPEC显示文摘Paolo Sammartino Simone Sibio Daniele Biacchi Maurizio Cardi Fabio Accarpio Pietro Mingazzini Maria Sofia Rosati Tommaso Cornali Angelo Di Giorgio Paul H. Sugarbaker 2012Gastroenterology Research and Practice2012,,:2
18A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer显示文摘Tristan D. Yan BSc (Med) MBBS Deborah Black BSc DipEd MStat PhD Paul H. Sugarbaker MD Jacqui Zhu BSc (Med) Yutaka Yonemura MD PhD George Petrou BSc (Med) MBBS David L. Morris MD PhD 2007Annals of Surgical Oncology2007,,10:2
19Analysis of Prognostic Factors in Seventy Patients Having a Complete Cytoreduction plus Perioperative Intraperitoneal Chemotherapy for Carcinomatosis from Colorectal Cancer显示文摘Rodrigo Gomes da Silva Paul H. Sugarbaker 2006Journal of the American College of Surgeons2006,,6:2
20Failure Analysis of Recurrent Disease Following Complete Cytoreduction and Perioperative Intraperitoneal Chemotherapy in Patients with Peritoneal Carcinomatosis from Colorectal Cancer显示文摘Lana Bijelic MD Tristan D. Yan BSc (Med) MBBS Paul H. Sugarbaker MD FACS FRCS 2007Annals of Surgical Oncology2007,,8:2
返回顶部 每页显示:
共4页 首页 上一页 第1页 下一页 末页 /4 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费